Autumn Glory Partners LLC Lowers Stock Holdings in Danaher Co. (NYSE:DHR)

Autumn Glory Partners LLC lowered its holdings in Danaher Co. (NYSE:DHR) by 52.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,320 shares of the conglomerate’s stock after selling 1,428 shares during the period. Autumn Glory Partners LLC’s holdings in Danaher were worth $303,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wedge Capital Management L L P NC grew its holdings in Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after buying an additional 38 shares in the last quarter. Meridian Financial Partners LLC boosted its stake in Danaher by 4.4% during the 3rd quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after purchasing an additional 40 shares in the last quarter. Kovack Advisors Inc. boosted its stake in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after purchasing an additional 41 shares in the last quarter. Well Done LLC boosted its stake in Danaher by 1.2% during the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock valued at $987,000 after purchasing an additional 42 shares in the last quarter. Finally, Waypoint Capital Advisors LLC boosted its stake in Danaher by 0.9% during the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after purchasing an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

DHR opened at $206.66 on Friday. The stock has a market cap of $149.26 billion, a price-to-earnings ratio of 39.14, a PEG ratio of 2.68 and a beta of 0.83. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a fifty day moving average price of $230.00 and a 200 day moving average price of $249.96.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the business earned $2.09 earnings per share. Analysts forecast that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.52%. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Analyst Ratings Changes

A number of equities analysts have issued reports on DHR shares. Barclays decreased their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Citigroup decreased their price target on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. JPMorgan Chase & Co. decreased their price target on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research note on Tuesday, January 28th. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Finally, UBS Group cut their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.